Robert Tjian

Robert Tjian

Director/Board Member at Innovative Genomics Institute

74 year
Miscellaneous
Consumer Services
Commercial Services

Profile

Robert Tjian is the founder of Eikon Therapeutics, Inc. He currently holds four positions as a Director at Neurona Therapeutics, Inc., Innovative Genomics Institute, and National Academy of Sciences, and as a Discovery Partner at The Column Group LLC.
He previously served as an Independent Director at Nurix Therapeutics, Inc. from 2016 to 2020 and as the President of Howard Hughes Medical Institute, Inc. (Investment Management) from 2009 to 2016.
He also held the position of President at Howard Hughes Medical Institute, Inc. and was a Faculty Member at the University of California, Berkeley.
Tjian received his undergraduate degree from the University of California, Berkeley in 1971 and his doctorate from Harvard University in 1976.

Robert Tjian active positions

CompaniesPositionStart
Corporate Officer/Principal 06/07/2011
Director/Board Member -
Innovative Genomics Institute Director/Board Member -
Private Equity Investor 01/09/2016
All active positions of Robert Tjian

Former positions of Robert Tjian

CompaniesPositionEnd
NURIX THERAPEUTICS, INC. Director/Board Member 01/11/2020
President 01/01/2016
Founder -
University of California, Berkeley Corporate Officer/Principal -
President -
See the detail of Robert Tjian's experience

Training of Robert Tjian

University of California, Berkeley Undergraduate Degree
Harvard University Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Tjian's experience

Connections

100 +

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
NURIX THERAPEUTICS, INC.

Health Technology

Private companies7

Miscellaneous

Miscellaneous

Commercial Services

Health Technology

Commercial Services

Innovative Genomics Institute

Finance

See company connections
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW